Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LAB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStandard BioTools reports Q2 revenue down 7.6% YoY, withdraws FY2026 guidance on Treeline merger
Filed August 5, 2026 · Period ending August 5, 2026 · ~1 min read
Key Changes
-
high
Q2 2026 revenue $20.1M, down 7.6% YoY from $21.8M; adjusted EBITDA loss improved 84% to $2.5M from $16.1M on 50% non-GAAP operating expense reduction
Exhibit 99.1 view on EDGAR → -
high
Recognized $172.3M gain and received $388.2M net cash from Mass Cytometry business sale; cash position strengthened to $541.1M from $227.9M year-earlier
Exhibit 99.1 view on EDGAR → -
high
Treeline merger progressing toward stockholder vote, expected to close before year-end 2026; FY2026 revenue guidance withdrawn due to pending merger
Exhibit 99.1 view on EDGAR → -
medium
Gross margin expanded to 52.4% from 48.8% YoY on productivity improvements and reduced warranty expense despite revenue decline
Exhibit 99.1 view on EDGAR →
Summary
Standard BioTools reported mixed Q2 2026 results as it transitions toward its transformational merger with Treeline Biosciences.
Revenue declined 7.6% year-over-year to $20.1 million, but the company demonstrated significant progress on profitability: adjusted EBITDA loss improved 84% to $2.5 million from $16.1 million, driven by a 50% reduction in non-GAAP operating expenses to $13.8 million following restructuring actions. Gross margin expanded 360 basis points to 52.4% despite the revenue headwind.
The company's strategic repositioning advanced with the Mass Cytometry business divestiture generating $388.2 million in net cash proceeds and a $172.3 million gain, strengthening the balance sheet to $541.1 million in cash and investments. Management withdrew full-year 2026 revenue guidance given the pending Treeline merger, which is progressing toward a stockholder vote and expected year-end close. The merger will shift Standard BioTools from life science tools to therapeutics development, with management citing exposure to a catalyst-rich pipeline as the rationale for maximizing shareholder value. Retail holders should monitor the merger vote timing and any updates on the Treeline pipeline assets that will define the combined entity's prospects.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Standard BioTools disclosed information under Regulation FD regarding full year 2026 revenue outlook.
Added in current filing · verify on EDGAR →
The information set forth under the headings “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.”, together with the forward-looking statement disclaimer, is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.
The company made a Regulation FD disclosure incorporating information about its full year 2026 revenue outlook and company description. The specific financial guidance or outlook details are referenced but not provided in the body of this 8-K filing.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Second quarter 2026 revenue of $20.1 million ... 1% improvement in operating loss and 84% improvement in adjusted EBITDA year-over-year
Standard BioTools reported Q2 2026 revenue of $20.1 million, down 7.6% year-over-year from $21.8 million. Despite the revenue decline, the company improved operating loss by 1% (from $25.7M to $25.4M) and adjusted EBITDA by 84% (from a loss of $16.1M to a loss of $2.5M), driven by cost discipline and previously announced restructuring actions. Gross margin expanded to 52.4% from 48.8% due to productivity improvements and reduced warranty expense.
Added in current filing · view on EDGAR →
Merger with Treeline Biosciences progressing toward stockholder vote and anticipated to close before year-end 2026
The company confirmed its merger with Treeline Biosciences is progressing toward a stockholder vote and is expected to close before year-end 2026. The registration statement on Form S-4 has been filed, and the company has agreed to divest its Mass Cytometry business. Illumina completed an early buyout of contingent payments for $30 million from its acquisition of SomaLogic. Management believes the merger is the best path to maximize shareholder value by providing exposure to a catalyst-rich, well-capitalized pipeline of potential new therapeutics.
Added in current filing · view on EDGAR →
Standard BioTools is withdrawing its full year 2026 revenue outlook given the pending merger with Treeline Biosciences.
The company withdrew its full year 2026 revenue guidance due to the pending merger with Treeline Biosciences. This withdrawal reflects the uncertainty and transition associated with the transformational merger, which will shift the company's focus from life science tools to therapeutics development.
Added in current filing · view on EDGAR →
Operating expenses in the second quarter of 2026 were $35.9 million, a decrease of $0.4 million, or down 1%, compared to the second quarter of 2025. Operating expenses included $14.7 million in transaction costs and $2.8 million in restructuring and related charges. Non-GAAP operating expenses, which exclude transaction costs, stock-based compensation, and restructuring charges, were $13.8 million in the second quarter of 2026, a decrease of $14.1 million, or down 50%, compared to the second quarter of 2025.
While GAAP operating expenses decreased only 1% year-over-year to $35.9 million (due to $14.7 million in transaction costs and $2.8 million in restructuring charges), non-GAAP operating expenses fell 50% to $13.8 million from $27.9 million, reflecting the impact of previously announced restructuring actions. This cost discipline was a key driver of the 84% improvement in adjusted EBITDA.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 6, 2026 · How we verify